Mitigating contrast-induced acute kidney injury associated with cardiac catheterization

Mark Nunag, Maureen Brogan, Renee Garrick

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Contrast-induced nephropathy, also referred to as contrast-induced acute kidney injury (CIAKI), is among the most common causes of AKI, especially in patients with underlying chronic kidney disease. In addition to the increased cost engendered by the development of CIAKI, several studies have suggested the occurrence of AKI after cardiac procedures is associated with an increase in both morbidity and mortality. This increase in morbidity and mortality occurs after both intravenous and intra-arterial studies. This review focuses on relevant proposed pathophysiological mechanisms, risk factors, and current prophylactic strategies, which may reduce the incidence of CIAKI during cardiac angiographic imaging studies.

Original languageEnglish (US)
Pages (from-to)263-269
Number of pages7
JournalCardiology in review
Volume17
Issue number6
DOIs
StatePublished - Nov 1 2009
Externally publishedYes

Fingerprint

Cardiac Catheterization
Acute Kidney Injury
Morbidity
Mortality
Chronic Renal Insufficiency
Costs and Cost Analysis
Incidence

Keywords

  • Bicarbonate therapy
  • Cardiac angiography
  • Contrast-induced AKI
  • Contrast-induced nephropathy
  • N-acetylcysteine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Mitigating contrast-induced acute kidney injury associated with cardiac catheterization. / Nunag, Mark; Brogan, Maureen; Garrick, Renee.

In: Cardiology in review, Vol. 17, No. 6, 01.11.2009, p. 263-269.

Research output: Contribution to journalReview article

@article{fde6a7654aa345a8a19660ff844b5482,
title = "Mitigating contrast-induced acute kidney injury associated with cardiac catheterization",
abstract = "Contrast-induced nephropathy, also referred to as contrast-induced acute kidney injury (CIAKI), is among the most common causes of AKI, especially in patients with underlying chronic kidney disease. In addition to the increased cost engendered by the development of CIAKI, several studies have suggested the occurrence of AKI after cardiac procedures is associated with an increase in both morbidity and mortality. This increase in morbidity and mortality occurs after both intravenous and intra-arterial studies. This review focuses on relevant proposed pathophysiological mechanisms, risk factors, and current prophylactic strategies, which may reduce the incidence of CIAKI during cardiac angiographic imaging studies.",
keywords = "Bicarbonate therapy, Cardiac angiography, Contrast-induced AKI, Contrast-induced nephropathy, N-acetylcysteine",
author = "Mark Nunag and Maureen Brogan and Renee Garrick",
year = "2009",
month = "11",
day = "1",
doi = "10.1097/CRD.0b013e3181bc359d",
language = "English (US)",
volume = "17",
pages = "263--269",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Mitigating contrast-induced acute kidney injury associated with cardiac catheterization

AU - Nunag, Mark

AU - Brogan, Maureen

AU - Garrick, Renee

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Contrast-induced nephropathy, also referred to as contrast-induced acute kidney injury (CIAKI), is among the most common causes of AKI, especially in patients with underlying chronic kidney disease. In addition to the increased cost engendered by the development of CIAKI, several studies have suggested the occurrence of AKI after cardiac procedures is associated with an increase in both morbidity and mortality. This increase in morbidity and mortality occurs after both intravenous and intra-arterial studies. This review focuses on relevant proposed pathophysiological mechanisms, risk factors, and current prophylactic strategies, which may reduce the incidence of CIAKI during cardiac angiographic imaging studies.

AB - Contrast-induced nephropathy, also referred to as contrast-induced acute kidney injury (CIAKI), is among the most common causes of AKI, especially in patients with underlying chronic kidney disease. In addition to the increased cost engendered by the development of CIAKI, several studies have suggested the occurrence of AKI after cardiac procedures is associated with an increase in both morbidity and mortality. This increase in morbidity and mortality occurs after both intravenous and intra-arterial studies. This review focuses on relevant proposed pathophysiological mechanisms, risk factors, and current prophylactic strategies, which may reduce the incidence of CIAKI during cardiac angiographic imaging studies.

KW - Bicarbonate therapy

KW - Cardiac angiography

KW - Contrast-induced AKI

KW - Contrast-induced nephropathy

KW - N-acetylcysteine

UR - http://www.scopus.com/inward/record.url?scp=73949122307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949122307&partnerID=8YFLogxK

U2 - 10.1097/CRD.0b013e3181bc359d

DO - 10.1097/CRD.0b013e3181bc359d

M3 - Review article

C2 - 19829174

AN - SCOPUS:73949122307

VL - 17

SP - 263

EP - 269

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 6

ER -